AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22323297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body immersion in warm water at 42°C for 40 min (HOT)
Number of subjects: 7
Study 20187757 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred self-care intervention (CCSCI)
Number of subjects: 40
Study 20187757 — intervention group
Group type: COMPARATOR
Intervention: Ordinary training (Control group)
Number of subjects: 40
Study 18005311 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip irrigation kits
Number of subjects: 396
Study 18005311 — intervention group
Group type: EXPERIMENTAL
Intervention: Watering cans with caps from a height <0.5 m
Number of subjects: 396
Study 18005311 — intervention group
Group type: COMPARATOR
Intervention: Watering cans without caps from a height >1 m
Number of subjects: 396
Study 16184030 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPD 25, 100, 200, 300 or 500 mg twice daily or 600 mg once daily monotherapy
Number of subjects: 90
Study 16184030 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPD 500 mg twice daily
Number of subjects: 90
Study 16184030 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPD 300 or 500 mg twice daily added to existing ART
Number of subjects: 90
Study 16184030 — intervention group
Group type: COMPARATOR
Intervention: Control group (ART‐experienced patients receiving existing ART)
Number of subjects: 90
Study 12577355 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhuhuang Frost (ZHF)
Number of subjects: 50
Study 12577355 — intervention group
Group type: COMPARATOR
Intervention: Mayinglong Musk hemorrhoidal paste (MMHP)
Number of subjects: 50
Study 9531251 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/d + Ticlopidine 2X250 mg/d (Group A)
Number of subjects: 61
Study 9531251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine 2X250 mg/d (Group B)
Number of subjects: 61
Study 9531251 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg/d (Group C)
Number of subjects: 61
Study 7980260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg bd for a minimum of 5 pre-operative days, then intravenously for 2 postoperative days)
Number of subjects: 50
Study 7980260 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine treatment)
Number of subjects: 50
Study 7980260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 50
Study 7980260 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 2481774 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10
Study 2481774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29076963 — intervention group
Group type: EXPERIMENTAL
Intervention: TR1 (3 × 10, 0-second rest)
Number of subjects: 10
Study 29076963 — intervention group
Group type: EXPERIMENTAL
Intervention: CL10 (3 × 10, 10-second rest)
Number of subjects: 10
Study 29076963 — intervention group
Group type: EXPERIMENTAL
Intervention: CL15 (3 × 10, 15-second rest)
Number of subjects: 10
Study 29076963 — intervention group
Group type: EXPERIMENTAL
Intervention: TR2 (6 × 5, 0-second rest)
Number of subjects: 10
Study 29076963 — intervention group
Group type: EXPERIMENTAL
Intervention: CL5 (3 × 10, 5-second rest)
Number of subjects: 10
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmitted drug resistance (TDR)
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs resistance
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTIs resistance
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: PIs resistance
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-class resistance
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: InSTIs resistance
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission clusters
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: TDR cluster
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment HIV resistance testing
Number of subjects: 403
Study 31754119 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance of TDR to InSTI
Number of subjects: 403
Study 28637418 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus 100 mg/day for 12 weeks
Number of subjects: 44
Study 25561192 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamshell incision (CI)
Number of subjects: 16
Study 25561192 — intervention group
Group type: COMPARATOR
Intervention: Left anterolateral thoracotomy (LAT)
Number of subjects: 16
Study 23733467 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg thrice daily)
Number of subjects: 31
Study 23733467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21791363 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Cardiac Resynchronization Therapy (LV CRT)
Number of subjects: 0
Study 21791363 — intervention group
Group type: COMPARATOR
Intervention: Biventricular Cardiac Resynchronization Therapy (Biventricular CRT)
Number of subjects: 0
Study 19537855 — intervention group
Group type: EXPERIMENTAL
Intervention: Brackets bonded within 24 hours after bleaching
Number of subjects: 38
Study 19537855 — intervention group
Group type: EXPERIMENTAL
Intervention: Brackets bonded 2-3 weeks after bleaching
Number of subjects: 38
Study 19537855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleached teeth
Number of subjects: 38
Study 19537855 — intervention group
Group type: COMPARATOR
Intervention: Unbleached teeth
Number of subjects: 38
Study 16946127 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5 mug) added to bosentan
Number of subjects: 67
Study 16946127 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to bosentan
Number of subjects: 67
Study 15464489 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (10 ng x kg(‐1) x min(‐1)) started 20 minutes before cross‐clamp removal and continued for 24 hours post-surgery
Number of subjects: 1190
Study 15464489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prostacyclin treatment)
Number of subjects: 1190
Study 11779437 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (Group I, n = 29)
Number of subjects: 55
Study 11779437 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (Group II, n = 26)
Number of subjects: 55
Study 9616522 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 1330
Study 8092830 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem monotherapy
Number of subjects: 280
Study 8092830 — intervention group
Group type: COMPARATOR
Intervention: Imipenem plus netilmicin
Number of subjects: 280
Study 3382463 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (7 X 100 mg for 3 days)
Number of subjects: 40
Study 3382463 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (7 X 100 mg for 3 days) + Vitamin B6 (7 X 40 mg)
Number of subjects: 40
Study 3382463 — intervention group
Group type: COMPARATOR
Intervention: Placebo or initial non-drug investigation
Number of subjects: 40
Study 30170260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) - 385.6 mg EPA and 81.2 mg DHA/capsule, n=33
Number of subjects: 99
Study 30170260 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) - 417.8 mg DHA and 50.8 mg EPA/capsule, n=33
Number of subjects: 99
Study 30170260 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high oleic acid sunflower oil), n=33
Number of subjects: 99
Study 29132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day) and Vitamin D3 (50,000 IU every two weeks) for 8 weeks
Number of subjects: 105
Study 29132734 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 105
Study 29132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and D3 supplementation
Number of subjects: 105
Study 29132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D level
Number of subjects: 105
Study 29132734 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular fluid or serum MDA and TAC
Number of subjects: 105
Study 26289681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative opioid use (11 to 30 TSDs)
Number of subjects: 3434
Study 26289681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative opioid use (31 to 90 TSDs)
Number of subjects: 3434
Study 26289681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative opioid use (91 or more TSDs)
Number of subjects: 3434
Study 26289681 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative NSAID use
Number of subjects: 3434
Study 26289681 — intervention group
Group type: EXPERIMENTAL
Intervention: Heaviest opioid use
Number of subjects: 3434
Study 26289681 — intervention group
Group type: COMPARATOR
Intervention: Little or no opioid or NSAID use
Number of subjects: 3434
Study 24123041 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m²) plus carboplatin (AUC=6 mg/ml min)
Number of subjects: 90
Study 24123041 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m²) plus carboplatin (AUC=6 mg/ml min)
Number of subjects: 90
Study 21235340 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine treatment (12 months)
Number of subjects: 434
Study 21235340 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment (12 months)
Number of subjects: 434
Study 17980970 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protease wound environment
Number of subjects: 2
Study 17980970 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protease wound environment
Number of subjects: 2
Study 16514112 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-times-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin
Number of subjects: 91
Study 12399345 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision support system
Number of subjects: 60
Study 12399345 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 60
Study 10445622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 parts per million (ppm) O3 exposure
Number of subjects: 13
Study 10445622 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 13
Study 7546130 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyol-containing saliva stimulants consumed voluntarily by residents of a VA Medical Center over a period of six to 30 months.
Number of subjects: 0
Study 2310660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (exact dosage and duration not specified)
Number of subjects: 0
Study 2310660 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (control group)
Number of subjects: 0
Study 426990 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg‐1
Number of subjects: 60
Study 426990 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 3.5 mg kg‐1
Number of subjects: 60
Study 6196556 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg prizidilol
Number of subjects: 12
Study 6196556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30972875 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 5074
Study 30972875 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 5074
Study 29383550 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal message promoting influenza vaccines
Number of subjects: 30000
Study 29383550 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR call promoting influenza vaccines
Number of subjects: 30000
Study 29383550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both portal message and IVR call
Number of subjects: 30000
Study 29383550 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) for portal users
Number of subjects: 30000
Study 29383550 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR call for non-portal users
Number of subjects: 30000
Study 29383550 — intervention group
Group type: COMPARATOR
Intervention: Usual care for non-portal users
Number of subjects: 30000
Study 26812861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 0
Study 26812861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25003289 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial
Number of subjects: 121
Study 22709754 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1024
Study 22709754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents (BMS)
Number of subjects: 1024
Study 22709754 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (MED)
Number of subjects: 1024
Study 20556560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR; 100‐250 mg twice daily)
Number of subjects: 2968
Study 20556560 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone hydrochloride controlled release (CR; 20‐50 mg twice daily)
Number of subjects: 2968
Study 20556560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 2968
Study 20556560 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR
Number of subjects: 2968
Study 17670782 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic atrial overdrive (AO) pacing algorithm activated
Number of subjects: 277
Study 17670782 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic atrial overdrive (AO) pacing algorithm deactivated
Number of subjects: 277
Study 17670782 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAF)
Number of subjects: 277
Study 16245247 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus interventional percutaneous transluminal renal artery stenting (PTRS)
Number of subjects: 100
Study 16245247 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 100
Study 12400976 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/day of megestrol acetate
Number of subjects: 119
Study 12400976 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg/day of megestrol acetate
Number of subjects: 119
Study 12400976 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/day and 320 mg/day of megestrol acetate
Number of subjects: 119
Study 10446821 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG group (n = 19), received a commercially available human IgA- and IgM-enriched immunoglobulin preparation (dose, 20 g)
Number of subjects: 40
Study 10446821 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 21), received physiologic saline
Number of subjects: 40
Study 10446821 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20), patients with normal immune responses
Number of subjects: 40
Study 7608311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine-CR 5 mg
Number of subjects: 402
Study 7608311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine-CR 10 mg
Number of subjects: 402
Study 7608311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine-CR 15 mg
Number of subjects: 402
Study 7608311 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine-CR 20 mg
Number of subjects: 402
Study 7608311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 2114240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (100 g)
Number of subjects: 8
Study 2114240 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal dose of GHRH (50 micrograms bolus, followed by 100 micrograms/h infusion for 3 h)
Number of subjects: 8
Study 390336 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated levodopa (Prodopa)
Number of subjects: 27
Study 390336 — intervention group
Group type: COMPARATOR
Intervention: Levodopa-carbidopa combination (Sinemet)
Number of subjects: 27
Study 31529024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 9361
Study 31529024 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 9361
Study 31693918 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP sugar-free chewing gum
Number of subjects: 19
Study 31693918 — intervention group
Group type: COMPARATOR
Intervention: No gum chewing
Number of subjects: 19
Study 26884063 — intervention group
Group type: EXPERIMENTAL
Intervention: MemPics™ (experimental group)
Number of subjects: 94
Study 26884063 — intervention group
Group type: COMPARATOR
Intervention: Control group activities
Number of subjects: 94
Study 25516380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine therapy
Number of subjects: 40
Study 23413951 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel combined with cisplatin (LP regimen)
Number of subjects: 126
Study 23413951 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine combined with cisplatin (GP regimen)
Number of subjects: 126
Study 21216683 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA) targeting a hemoglobin (Hb) level of 13 g/dL
Number of subjects: 4038
Study 21216683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4038
Study 21216683 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 4038
Study 19474264 — intervention group
Group type: EXPERIMENTAL
Intervention: PsA‐TT conjugate vaccine
Number of subjects: 0
Study 19474264 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal A/C polysaccharide vaccine (PsA/C)
Number of subjects: 0
Study 19474264 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid vaccine
Number of subjects: 0
Study 17879675 — intervention group
Group type: EXPERIMENTAL
Intervention: Strips system
Number of subjects: 26
Study 17879675 — intervention group
Group type: COMPARATOR
Intervention: Gel system
Number of subjects: 26
Study 15487436 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconscious control of semantic-level activation
Number of subjects: 0
Study 15487436 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious control of semantic-level activation
Number of subjects: 0
Study 15487436 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a competitor and desired reward
Number of subjects: 0
Study 15487436 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of a competitor and desired reward
Number of subjects: 0
Study 11991768 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of ginseng root extract (GIN)
Number of subjects: 8
Study 11991768 — intervention group
Group type: COMPARATOR
Intervention: Water (control; CON)
Number of subjects: 8
Study 9855767 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychorelaxation therapy based on biological feedback
Number of subjects: 43
Study 9855767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychorelaxation therapy)
Number of subjects: 43
Study 7534777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinonide ointment plus prolonged occlusion
Number of subjects: 19
Study 7534777 — intervention group
Group type: COMPARATOR
Intervention: Prolonged occlusion
Number of subjects: 19
Study 7534777 — intervention group
Group type: COMPARATOR
Intervention: Fluocinonide ointment
Number of subjects: 19
Study 2084586 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36
Study 2084586 — intervention group
Group type: COMPARATOR
Intervention: Diazepam and Fentanyl
Number of subjects: 36
Study 37870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (beta-blocker), given once daily
Number of subjects: 0
Study 37870 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (beta-blocker), given four times daily
Number of subjects: 0
Study 37870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol and Propranolol
Number of subjects: 0
Study 31780346 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT‐SE (8-session cognitive behaviour therapy group intervention)
Number of subjects: 0
Study 31780346 — intervention group
Group type: COMPARATOR
Intervention: Control (only supported employment program)
Number of subjects: 0
Study 30817739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium enhancement of the disc herniation
Number of subjects: 119
Study 30817739 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium enhancement of the nerve root
Number of subjects: 119
Study 30817739 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of inflammation by macrophages
Number of subjects: 119
Study 30817739 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of patient groups with and without Modic type 2 changes
Number of subjects: 119
Study 30817739 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Modic type 2 changes
Number of subjects: 119
Study 29685828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10°C Cold Water Immersion (CWI) for 10 minutes
Number of subjects: 33
Study 29685828 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 33
Study 26309227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone during radiotherapy for 14 days
Number of subjects: 53
Study 26309227 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 53
Study 25709122 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous exercise training program (8 weeks, 60‐79% HR reserve, 45-60 minutes, 3 times per week)
Number of subjects: 357
Study 25709122 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 357
Study 22436337 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual interventions (e.g. manipulation, mobilization or soft tissue techniques)
Number of subjects: 38
Study 22436337 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 38
Study 22436337 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up sessions 2 and 3
Number of subjects: 38
Study 18766426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg daily, ≤100 mg/day)
Number of subjects: 86
Study 18766426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86